Snodig, i prospektet for rep-emi var det 67 i 20 av 20 land.
(Jeg baserer meg pĂ„ MrSpecials â69 av 23â, jeg har ikke sjekket de tallene selv.)
NÄr de rapporterer land sÄ er det regulatorisk de snakker om. Det er ikke nÞdvendigvis sites i alle disse landa.
@ath100, enig i at dette er litt snodig, da de siden prospektet ble utarbeidet har Þkt antall sites med 2, men antall land med 3. Det er et regnestykke jeg sliter med Ä fÄ til Ä gÄ opp 
Uansett, om dette er en skrivefeil eller ikke, sÄ er det positivt og betryggende at antall Äpne sites og antall land er bedre enn hva de fleste av oss hadde forventet. Det viser at de er ontrack (som jo er det viktigste), og at det i et best case scenario faktisk vil kunne rekrutteres og avleses data raskere enn hva som er guidet.
Edit: @anon21766851 kom med en Äpenbar avklaring pÄ "mismatchen " mellom Þkning i antall land og antall sites. Takk 
Cashburnen var vel reellt 96 mill, men renteinntekter etc gjorde at /cashburn ble pĂ„virket positivt/cashbeholdningen steg noe igjenâŠ
ForÞvrig, basert pÄ regnestykker som har blitt lagt frem her inne, sÄ virker enrolment completed for Paradigme i H1 2020 veldig defensivt.
Enig i dette. Bravo nevnte vel ogsÄ noe om at man forhÄpentligvis slapp Ä fortsette Ä oppdatere pÄ antall sites etter q1 fordi alle sites da forhÄpentligvis var up and running
Driftskostnader var 96m, cashburn(kontantstrĂžm) var 59m nok tror jeg er rett Ă„ lese ja.
Lignende forhold skjedde i Q417, 102m nok i driftskostnader, 47,2m nok i cashburn. Betydelig hyggeligere Ăžkonomisk posisjon enn noen hadde antatt. =]
Har Patrik Ling oppdatert analysen sin?
Patrik who ??? 
Her er transkriptet fra dagens q4-presentasjon. Fra Yahoo Finance. Enjoy!
https://finance.yahoo.com/news/edited-transcript-nano-ol-earnings-182200608.html
Oppsummering fra DnB.
Q4 results a non-event
Nordic Nanovector reported an operating loss for Q4, with the results a non-event per se. Management highlighted that the recruitment of sites for the pivotal phase II PARADIGME trial is progressing well, and as of 26 February the trial had been approved in 69 centres in 23 countries. Following Februaryâs private placement, we believe the company has sufficient cash to manage operations until after data read-out for PARADIGME in H1 2020e. We reiterate our BUY recommendation and NOK110 target price.
cNOK96m operating loss in Q4 . This was slightly higher than we had expected (we estimated a loss of cNOK85m). However, the cNOK440m cash balance at quarter-end was higher than we had forecast, due to positive movements in non-cash items and interest income. In addition, the company raised cNOK222m (before costs) in February in a private placement, taking the pro forma cash position up to cNOK660m.
Site recruitment for PARADIGME progressing well . As of 26 February], the company had 69 sites enrolled in the trial in 23 countries; the target is 80â85 sites recruiting a total of c130 patients. We do not know how many patients have actually been treated, but the company reiterated that it expects the trial to be fully enrolled by Q1 2020 and data read-out in Q2 2020.
We expect an update on the phase I/II data on duration of response (DoR) at ASH in December, but do not expect the response numbers to have moved in any particular direction, rather the ORR is expected in our view to be around c65% and the CR around c25%. However, we will be looking to see if the DoR has improved from the nine months revealed at ASH2018.
We like the risk/reward value proposition for Betalutin . The risk/reward for a product like Betalutin looks good in our view and we believe the regulatory authorities will look at it the same way. We have seen in recent FDA documentations that getting the risk/reward right is crucial for early approval.
BUY recommendation and NOK110 target price reiterated . We believe the company is sufficiently financed over the PARADIGME data read-out trigger in Q2 2020e. Our forecast adjustments reflect higher R&D spend going forward as they run more trials.
Hver mÄned kÄrer jeg det jeg kaller Teksperter⹠for noen av de mest populÊre investeringene vÄre
Det er de 3 medlemmene som har fĂ„tt flest likes pĂ„ innleggene sine de siste 90 dagene. Teksperterâą fĂ„r ogsĂ„ en unikt merke pĂ„ profilen sin og et trofĂ©-ikon ved siden av navnet sitt. Du kan bli Tekspertâą i flere aksjer/investeringer, og trofĂ©et vil bare vises i trĂ„der der du er Tekspertâą.
Her er denne mÄnedens Teksperter⹠og det mest likte innlegget deres fra de siste 90 dagene:
- @studenten86 (1112 likes)
- @Savepig (1101 likes)
- @Nocturne (511 likes)
Resten av topp 10:
-
@Krieghoff (448 likes)
-
@anon21766851 (410 likes)
-
@TyrionIV (370 likes)
-
@Inkognito666 (315 likes)
-
@Bra_Britt (294 likes)
-
@InVivo (275 likes)
-
@Oilimp (275 likes)
Gratulerer!
Nice den der Savepig! ARCHER-1 blir bare mer og mer lovende!
«These findings give novel insights into the mechanisms of synergy in antibody-mediated complement-dependent cytotoxicity and provide a rationale to explore Fc-engineering and antibody hetero-hexamerization as a tool to enhance the cooperativity and therapeutic efficacy of antibody combinations.»
04/03-2019 13:27:00: (NANO) Nordic Nanovector ASA: Increase of share capital
Noen som har oversikt over hva vÄr venn Sandnes betaler for RSUene.?